Literature DB >> 32038910

Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?

Maria A Velez1, Timothy F Burns2,3.   

Abstract

Entities:  

Year:  2019        PMID： 32038910      PMCID： PMC6987364          DOI： 10.21037/tlcr.2019.04.09

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  19 in total

1.  The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.

Authors:  Nan Zhang; Yuanyuan Zeng; Wenwen Du; Jianjie Zhu; Dan Shen; Zeyi Liu; Jian-An Huang
Journal:  Int J Oncol       Date:  2016-07-26       Impact factor: 5.650

Review 2.  Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.

Authors:  Ross A Soo; Sun Min Lim; Nicholas L Syn; Rebecca Teng; Richie Soong; Tony S K Mok; Byoung Chul Cho
Journal:  Lung Cancer       Date:  2017-11-13       Impact factor: 5.705

3.  Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Authors:  Nan Chen; Wenfeng Fang; Jianhua Zhan; Shaodong Hong; Yanna Tang; Shiyang Kang; Yaxiong Zhang; Xiaobo He; Ting Zhou; Tao Qin; Yan Huang; Xianping Yi; Li Zhang
Journal:  J Thorac Oncol       Date:  2015-06       Impact factor: 15.609

4.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

Review 5.  Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.

Authors:  Zhong-Yi Dong; Si-Pei Wu; Ri-Qiang Liao; Shu-Mei Huang; Yi-Long Wu
Journal:  Tumour Biol       Date:  2016-01-16

6.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.

Authors:  K Azuma; K Ota; A Kawahara; S Hattori; E Iwama; T Harada; K Matsumoto; K Takayama; S Takamori; M Kage; T Hoshino; Y Nakanishi; I Okamoto
Journal:  Ann Oncol       Date:  2014-07-09       Impact factor: 32.976

7.  Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.

Authors:  Fabio Conforti; Laura Pala; Vincenzo Bagnardi; Tommaso De Pas; Marco Martinetti; Giuseppe Viale; Richard D Gelber; Aron Goldhirsch
Journal:  Lancet Oncol       Date:  2018-05-16       Impact factor: 41.316

8.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

9.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Authors:  Hira Rizvi; Francisco Sanchez-Vega; Konnor La; Walid Chatila; Philip Jonsson; Darragh Halpenny; Andrew Plodkowski; Niamh Long; Jennifer L Sauter; Natasha Rekhtman; Travis Hollmann; Kurt A Schalper; Justin F Gainor; Ronglai Shen; Ai Ni; Kathryn C Arbour; Taha Merghoub; Jedd Wolchok; Alexandra Snyder; Jamie E Chaft; Mark G Kris; Charles M Rudin; Nicholas D Socci; Michael F Berger; Barry S Taylor; Ahmet Zehir; David B Solit; Maria E Arcila; Marc Ladanyi; Gregory J Riely; Nikolaus Schultz; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2018-01-16       Impact factor: 44.544

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245
View more
  7 in total

1.  Comparing Findings From a Friends of Cancer Research Exploratory Analysis of Real-World End Points With the Cancer Analysis System in England.

Authors:  Pia Horvat; Christen M Gray; Alexandrina Lambova; Jennifer B Christian; Laura Lasiter; Mark Stewart; Jeff Allen; Paul Clarke; Cong Chen; Adam Reich
Journal:  JCO Clin Cancer Inform       Date:  2021-12

2.  Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors.

Authors:  Andrea M Chambers; Kyle B Lupo; Jiao Wang; Jingming Cao; Sagar Utturkar; Nadia Lanman; Victor Bernal-Crespo; Shadia Jalal; Sharon R Pine; Sandra Torregrosa-Allen; Bennett D Elzey; Sandro Matosevic
Journal:  Elife       Date:  2022-07-11       Impact factor: 8.713

Review 3.  Immunotherapy in oncogene addicted non-small cell lung cancer.

Authors:  Luke McLean; Jose Luis Leal; Benjamin J Solomon; Thomas John
Journal:  Transl Lung Cancer Res       Date:  2021-06

4.  High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy.

Authors:  Shibo Wu; Guodong Li; Xin Zhao; Jianxing Xiang; Analyn Lizaso; Junyi Ye; Chunlei Shi; Lingxiang Chen
Journal:  Ann Transl Med       Date:  2020-06

5.  Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma.

Authors:  Lei Sun; Wen-Ke Liu; Xiao-Wei Du; Xiang-Li Liu; Gao Li; Yao Yao; Tao Han; Wen-Ya Li; Jia Gu
Journal:  Ann Transl Med       Date:  2020-06

6.  Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma.

Authors:  Ke Ma; Yulei Qiao; Hao Wang; Shuai Wang
Journal:  Ann Transl Med       Date:  2020-11

7.  Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.

Authors:  Jiaqi Liang; Ming Li; Qihai Sui; Zhengyang Hu; Yunyi Bian; Yiwei Huang; Cheng Zhan; Wei Jiang; Qun Wang; Lijie Tan
Journal:  Transl Lung Cancer Res       Date:  2020-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.